当前位置: 首页 >> 检索结果
共有 16822 条符合本次的查询结果, 用时 5.5301308 秒

1061. Effects of semaglutide on heart failure outcomes - Author's reply.

作者: John Deanfield.
来源: Lancet. 2025年405卷10478期543-544页

1062. Effects of semaglutide on heart failure outcomes.

作者: Jiashu Han.;Dan Shan.
来源: Lancet. 2025年405卷10478期542页

1063. Effects of semaglutide on heart failure outcomes.

作者: João Sérgio Neves.;Milton Packer.;João Pedro Ferreira.
来源: Lancet. 2025年405卷10478期542-543页

1064. Generation C: the scope and effects of paediatric long COVID.

作者: Naomi Ketharanathan.;Karolijn Dulfer.;Matthijs de Hoog.;Marieke Otten.;Corinne Buysse.
来源: Lancet. 2025年405卷10478期541-542页

1065. Testing hearing in suspected stroke: a diagnostic opportunity.

作者: Nehzat Koohi.;Syuzanna Simonyan.;Lucia Joffily.;Robert Simister.;Doris-Eva Bamiou.;Diego Kaski.
来源: Lancet. 2025年405卷10478期540-541页

1066. Offline: Telling the truth about WHO.

作者: Richard Horton.
来源: Lancet. 2025年405卷10478期529页

1067. Ischaemic brain neuroprotection: a true therapeutic frontier?

作者: Ava L Liberman.;Steven R Levine.
来源: Lancet. 2025年405卷10478期519-521页

1068. Philanthropy for health: past, present, and future.

作者: The Lancet.
来源: Lancet. 2025年405卷10478期517页

1069. The Lancet Commission on Transforming Primary Health Care in the Post-COVID-19 Era.

作者: William Chi-Wai Wong.;Vivian Lin.;Xiaoxuan Fang.;Michael Kidd.; .
来源: Lancet. 2025年405卷10478期527-528页

1070. PEPFAR under review: what's at stake for PEPFAR's future.

作者: Jirair Ratevosian.;Gregorio Millett.;Brian Honermann.;Sara Bennett.;Catherine Connor.;Linda-Gail Bekker.;Chris Beyrer.
来源: Lancet. 2025年405卷10479期603-605页

1071. A new pathway for primary aldosteronism treatment.

作者: Alexander A Leung.;Gregory Kline.
来源: Lancet. 2025年405卷10479期599-601页

1072. Health-care system adaptability during wildfire disasters: crucial insights from LA County.

作者: Attila J Hertelendy.;Jeremy Maggin.;Gregory R Ciottone.
来源: Lancet. 2025年405卷10479期621-622页

1073. Endoscopic, ultrasound-guided, radiofrequency ablation of aldosterone-producing adenomas (FABULAS): a UK, multicentre, prospective, proof-of-concept trial.

作者: Giulia Argentesi.;Xilin Wu.;Alexander Ney.;Emily Goodchild.;Kate Laycock.;Yun-Ni Lee.;Russell Senanayake.;James MacFarlane.;Elisabeth Ng.;Jessica Kearney.;Sam O'Toole.;Jackie Salsbury.;Nick Carroll.;Daniel Gillett.;John A Tadross.;Alison Marker.;Edmund M Godfrey.;George Goodchild.;Jonathan P Bestwick.;Mark Gurnell.;Heok Cheow.;Stephen P Pereira.;William M Drake.;Morris J Brown.; .
来源: Lancet. 2025年405卷10479期637-647页
Unilateral aldosterone-producing adrenal adenomas (APAs) are the potentially curable cause of 5% of all cases of hypertension. Their localisation (via adrenal vein sampling [AVS]) and removal (by laparoscopic adrenalectomy) require invasive procedures that are unattractive to patients. Molecular imaging-located, endoscopic ultrasound-guided trans-gastric radiofrequency ablation (EUS-RFA) is a potential novel, minimally invasive alternative to AVS and total adrenalectomy for the treatment of APAs in the left adrenal gland, which is very close to the stomach. We aimed to determine whether EUS-RFA can safely target a heterogeneous set of such tumours without damaging the rest of the adrenal gland or adjacent organs.

1074. Gender removal by fiat: impacts of new Trump administration edicts.

作者: Nancy Krieger.;Sofia Gruskin.
来源: Lancet. 2025年405卷10479期620页

1075. Angola's cholera outbreak: a wake-up call for global action.

作者: Mauer Alexandre da Ascensão Gonçalves.;Howard Lopes Ribeiro Júnior.
来源: Lancet. 2025年405卷10479期620-621页

1076. Faustine Ndugulile.

作者: Andrew Green.
来源: Lancet. 2025年405卷10477期460页

1077. Ukraine HIV services severely curtailed by US aid freeze.

作者: Ed Holt.
来源: Lancet. 2025年405卷10477期455页

1078. Health worker lay-offs in east Africa following US aid freeze.

作者: Gilbert Nakweya.
来源: Lancet. 2025年405卷10477期454页

1079. Trump agenda ignites legal challenges.

作者: Susan Jaffe.
来源: Lancet. 2025年405卷10477期452-453页

1080. Pregnancy and the liver.

作者: Mussarat N Rahim.;Catherine Williamson.;Nikos A Kametas.;Michael A Heneghan.
来源: Lancet. 2025年405卷10477期498-513页
Some of the physiological changes that occur in pregnancy manifest in the liver. These alterations might exacerbate or improve some pre-existent liver diseases, while many conditions remain unaffected. Some hepatic manifestations during pregnancy are secondary to disorders unique to pregnancy. Due to improved management of chronic conditions and assisted conception methods, pregnancies in people with cirrhosis or after liver transplantation are increasingly common. With pregnancy also becoming more common in older people and with the rising prevalence of comorbidities, such as obesity, diabetes, and metabolic syndrome, hypertensive disorders of pregnancy and gestational diabetes are increasing in prevalance. Thus, a broad range of specialists might encounter liver abnormalities in pregnancy, necessitating an understanding of how the liver changes during pregnancy and the importance of multi-disciplinary input to mitigate maternal-fetal risks. From a global health perspective, pregnancy also offers a unique opportunity to influence disease management and initiate interventions that might influence the life course of pregnant people and their families. In this Review, we describe the challenges of diagnosing, risk stratifying, and managing liver disease in pregnancy, and explore factors that might affect future maternal health.
共有 16822 条符合本次的查询结果, 用时 5.5301308 秒